Special Issue

Extracellular Vesicles and Lipid Nanoparticles in Cardiovascular Diseases

Message from the Guest Editor

This Special Issue encourages authors to develop innovative solutions by concurrently exploring extracellular vesicles and lipid nanoparticles. Extracellular vesicles (EVs) have recently emerged as pivotal mediators in intercellular communication during cardiovascular development and pathophysiology, with exosomal non-coding RNAs offering promise as diagnostic and prognostic biomarkers for CVDs. Simultaneously, lipid nanoparticles (LNPs) present themselves as versatile carriers, offering potential solutions for targeted drug delivery in cardiovascular therapies. This Research Topic seeks original research and review articles, offering to provide a platform to research navigating challenges such as EV/LNP manufacturing, RNA-loaded EVs/LNPs, and targeted delivery. Authors are encouraged to delve into diverse themes, from the differentiation of cardiovascular cells to diagnostic innovations and cardiovascular homeostasis, fostering a comprehensive understanding of both extracellular vesicles and lipid nanoparticles in the context of cardiovascular translational medicine.

Guest Editor

Dr. Junlang Li

1. Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, USA
2. Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill & Raleigh, NC, USA

Deadline for manuscript submissions

closed (31 December 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/192679

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).